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a b s t r a c t
T helper type 1 (Th1) immunity was considered to play a dominant role in viral clearance of
hepadnaviral infection. However, pre-primed Th2 type responses were able to efﬁciently control
hepadnaviral infection in animal models. We investigated how pre-primed Th1/2 responses control
hepadnaviral replication using the newly established mouse models. DNA (pWHcIm, pCTLA-4-C) and
protein vaccines based on the nucleocapsid protein (WHcAg) of woodchuck hepatitis virus (WHV)
primed speciﬁc immune responses with distinct features. The pre-primed responses determined the
characteristics of recall responses if challenged with a WHcAg-expressing adenoviral vector. Vaccination
with pWHcIm and pCTLA4-C facilitated viral control in the hydrodynamic injection model and reduced
WHV loads by about 3 and 2 logs in WHV-transgenic mice, respectively, despite of different kinetics of
speciﬁc CD8þ T cell responses. Thus, pre-primed Th2-biased responses facilitate the development of
CD8þ T cell responses in mice compared with naïve controls and thereby confer better viral control.
& 2014 Published by Elsevier Inc.
Introduction
Hepatitis B virus (HBV) infection is a global public health
problem, as more than 350 million people worldwide are chroni-
cally infected with HBV and at high risk for developing severe liver
diseases, such as cirrhosis and hepatocellular carcinoma. The
prophylactic vaccine based on HBV surface antigen (HBsAg) has
been successfully used since 1980 and can effectively induce
protective anti-HBs antibodies, which neutralize HBV particles.
Current research focuses on the development of therapeutic
vaccines for the treatment of chronic HBV infection. HBV clearance
following primary infection requires the appropriate host immune
responses, including both humoral and cellular immune responses
(Chisari and Ferrari, 1995; Rehermann and Nascimbeni, 2005).
HBV-speciﬁc cytotoxic T cells (CTLs) targeting HBsAg, HBV core
protein (HBcAg), and the viral polymerase have been detected in
HBV-infected individuals and are associated with HBV clearance
(Phillips et al., 2010; Thimme et al., 2003). Chronically infected
patients show immunotolerance to the HBV proteins, with no
production of anti-HBs antibodies and very low or undetectable
HBV-speciﬁc CTL responses. Restoration of the HBV-speciﬁc
immune response in chronic HBV carriers is a potential strategy
for achieving control of the infection or even for curing patients
(Kosinska et al., 2010; Maini and Schurich, 2010). However, clinical
trials with various vaccine formulations including DNA based
vaccines and the HBsAg-HBs antibody immunogenic complexes
were not as successful as initially anticipated (Mancini-Bourgine
et al., 2004; Michel and Deng and Mancini-Bourgine, 2011; Xu et
al., 2013, 2008; Yang et al., 2006).
One major uncertainty for the immunotherapeutic approach is
the suitability of used vaccines. In general, vaccines that prime
Th1-dominant immune responses to HBV were considered as
better candidates for prophylactic and immunotherapeutic
approaches. However, an early publication reported that HBcAg
immunizations conferred partial protection against HBV challenge
in chimpanzees (Iwarson et al., 1985). Later, Schodel et al. (1993a)
showed that vaccination of woodchucks with WHcAg protein
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protected them against WHV challenge. Menne et al. (1997) used a
WHcAg-derived peptide to immunize woodchucks, achieving
efﬁcient protection against WHV challenge. We previously found
that a CTLA-4-WHcAg fusion plasmid induced Th2-dominant
immune responses but was similarly protective when compared
to a plasmid that induces Th1-dominant responses to WHcAg (Lu
et al., 2005). Furthermore, we demonstrated that pre-primed Th2-
dominant immune responses to HBcAg efﬁciently cleared HBV
from the host in the HBV mouse model (Yin et al., 2011). Thus,
different vaccine types should not only be judged on the basis of
primed immune responses and needs to be tested for their ability
to control HBV infection in in vivomodels. In addition, the mode of
protection after the vaccinations was not analysed in details in the
previous studies.
Therefore, it is essential to analyze the host immune responses
post challenge to understand how vaccine-induced immune
responses determine the process of viral clearance. The wood-
chuck model is a useful animal model for studies on HBV infection.
Woodchucks can be infected with woodchuck hepatitis virus
(WHV), a genetically closely related virus to HBV. The woodchuck
model has been used to test different approaches for immunomo-
dulation and immunotherapy of chronic HBV infection. As men-
tioned above, a number of protein- and DNA-based vaccines were
tested in challenge studies in the woodchuck model and showed
the ability to protect. However, due to the lack of required
immunological reagents for the woodchuck model, it is yet not
possible to characterize the ﬁne features of vaccine-induced
immune responses and the mechanisms of viral control in wood-
chucks. Recently, we established two new mouse models to
studies on WHV replication and WHV-speciﬁc immune responses.
In this way, the features of WHV-speciﬁc immune responses could
be determined more precisely, for example, by distinguishing Th
types. In this study, we explored WHV-speciﬁc vaccines for the
experimental approaches in the novel mouse models. We char-
acterized the different types of speciﬁc immune responses primed
by DNA and protein vaccines to WHcAg and tested the combina-
tions of the different vaccine types. Viral challenges with adeno-
viral vectors expressing WHcAg and by hydrodynamic injection
with WHV were performed to examine the recall responses and
viral clearance. Two different WHcAg DNA vaccines were also
tested in WHV transgenic (tg) mice, demonstrating that both
vaccines were able to induce speciﬁc immune responses and to
suppress WHV replication, though many features of the induced
speciﬁc immune responses may differ strongly.
Results
Priming of qualitatively distinct WHcAg-speciﬁc immune responses
using DNA and WHcAg protein vaccines
Previous experiments demonstrated that DNA and WHcAg
protein vaccines were able to stimulate WHcAg-speciﬁc immune
responses in mice and to confer a certain degree of protection
against WHV challenge in woodchucks (Kosinska et al., 2012, 2010;
Lu et al., 2005; Menne et al., 1997). To accurately deﬁne the
different features of WHcAg-speciﬁc immune responses primed by
these vaccines, C57BL/6 mice were immunized three times with
each vaccine. The DNA vaccines pWHcIm and pCTLA-4-C and the
WHcAg protein vaccine induced anti-WHcAg antibodies (Fig. 1A).
As IL-4 from T helper 2 CD4 cells induces IgG1 while IFN-γ from T
helper 1 CD4 cells induces IgG2a production in mice, antigen-
speciﬁc IgG subtype IgG1 and 2a were used to approximately
classify the speciﬁc response (Stevens et al., 1988). The WHcAg-
speciﬁc immune responses were classiﬁed as Th1 or Th2 type
according to the WHcAg-speciﬁc IgG subtype IgG1 and 2a.
Consistent with previous ﬁndings, pWHcIm preferentially induced
antibodies of the IgG2a subtype, while both IgG2a and IgG1
antibodies were found in mice immunized with pCTLA-4-C and
WHcAg protein. Furthermore, the IFN-γ secreting CD4 and CD8
cells, which were belonging to Th1 type response were charac-
terised to precisely identify the types of WHcAg-speciﬁc response.
WHcAg-speciﬁc T cell responses in immunized mice were assessed
by detection of IFN-γþ T cells after a 7-day in vitro stimulation of
splenocytes with the appropriate WHcAg-derived peptides (Fig.
S1A, Fig. 1B). Immunizations with pWHcIm elicited strong
WHcAg-speciﬁc CD8þ and lower but clearly detectable CD4þ T
cell responses. Mice immunized with pCTLA-4-C had very limited
CD8þ T cell responses, but signiﬁcant CD4þ T cell responses were
detected. In contrast, no detectable CD4þ or CD8þ T cell response
was induced in WHcAg-immunized mice (Fig. 1B). Antigen-speciﬁc
CD8þ T cells in pWHcIm-immunized mice showed both IFN-γ
production and degranulation, indicating that these antigen-
speciﬁc T cells were functional CTLs (Fig. 1C). The in vivo cytotoxi-
city assay demonstrated that killing of target cells loaded with
WHcAg-derived peptide p13-21 only occurred in mice immunized
with pWHcIm but not in the other vaccination groups (Fig. S1B,
Fig. 1D). These results indicated that pWHcIm induced a typical
Th1-dominant immune response, while immunization with
pCTLA-4-C shifted the WHcAg-speciﬁc immune response towards
a Th2-dominant type. WHcAg protein induced a Th2 type response
without a detectable T cell component (Table 1).
WHcAg-speciﬁc recall responses after administration of a WHcAg-
expressing adenoviral vector were strongly inﬂuenced by the pre-
primed responses
Next we addressed the question about the speciﬁc recall
responses in mice received different DNA and protein vaccines
after re-exposure to WHcAg. First, the mice were primed with
pWHcIm or WHcAg twice and then boosted with heterologous
vaccines WHcAg or pWHcIm, respectively (see supplementary
text). The results showed that the speciﬁc immune responses
and the function of CTLs in vaccinations with heterologous prim-
ing and boost could be complex but were strongly determined by
the type of vaccines applied for the boost (Figs. S2 and S3). The
application of WHcAg protein in our experiments signiﬁcantly
inhibited the induction of WHcAg-speciﬁc CD8þ T cells, likely due
to the priming of the Th2 dominance. These results hint that the
way of the latest encounter with WHcAg may inﬂuence the recall
responses and thereby modulate the speciﬁc T and B responses.
To achieve intrahepatic WHcAg expression and study the recall
responses after intrahepatic challenge that is relevant for hepad-
naviral infection, a replication-incompetent adenoviral vector
genotype 5 expressing WHcAg (Ad5WHc) was constructed
(Kosinska et al., 2012). We showed that Ad5WHc induces strong
T cell and antibody responses to WHcAg in mice if applied by
intramuscular injection. Intravenous injection of Ad5WHc led to
the accumulation mainly in the liver within 48 h and only a very
low level in the other organs (Fig. 2A). This fact allows us to
characterize the recall response after intrahepatic expression of
WHcAg. Mice were immunized three times with pWHcIm, pCTLA-
4-C, or WHcAg as described above. Two weeks later, the immu-
nized mice received intravenously 11010 pfu Ad5WHc and were
sacriﬁced on days 4, 7, and 10 (Fig. 2B). Ad5WHc disappeared from
the liver with similar kinetics in mice of different groups, indicat-
ing that its clearance was not related to the pre-existing immune
responses (Fig. 2C).
Ad5WHc administration in immunized mice induced rapid and
vigorous T cell responses to WHcAg, allowing the analysis of
WHcAg-speciﬁc T cell recall responses using ex vivo assays. The
functionality of speciﬁc T cells to WHcAg p13-21 was evaluated by
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measuring degranulation and cytokine production using ex vivo
staining to detect CD107a, IFN-γ, TNF-α, and IL-2. A rapid and
strong CD8þ T cell recall response to WHcAg p13-21 developed by
day 4 in mice immunized with pWHcIm and decreased by days
7 and 10. The majority of WHcAg-speciﬁc CD8þ T cells were
double positive for CD107a and IFN-γ (Fig. 2D). In mice immunized
with pCTLA-4-C or WHcAg, WHcAg-speciﬁc CD8þ T cells were
initially absent and appeared at lower levels with delayed kinetics
after Ad5WHc administration. Detectable CD8þ T cell responses to
WHcAg p13-21 arose on day 7 at a low frequency and decreased
on day 10. Consistent with the results of the prime-boost immu-
nization described above, mice that received the pCTLA-4-C DNA
vaccine had higher levels of CD8þ IFN-γþ T cells than mice
immunized with WHcAg. In all conditions, CD8þ T cells expres-
sing IFN-γ, TNF-α, and IL-2 were found following Ad5WHc
challenge (Fig. 2E), however, the phenotypes of speciﬁc CD8þ T
cells could not be analysed in details due to the low frequencies.
Taken together, the nature and magnitude of WHcAg-speciﬁc
recall T cell responses following Ad5WHc challenge in mice was
strongly inﬂuenced by the preceding vaccinations. The strongest
WHcAg-speciﬁc CD8þ T cell responses were detected in mice
immunized with pWHcIm.
Primed Th1 or Th2 type immune responses to WHcAg facilitated viral
reduction after WHV challenge by HI
To assess the protective values of different types of immune
responses, we established the HI model of WHV challenge in
immunized mice. A plasmid, pBS/WHV-Sa1.3, contains a 1.3-fold
overlength WHV genome was used (Pan et al., manuscript under
Fig. 1. WHcAg-speciﬁc immune responses in C57BL/6 mice primed by pWHcIm, pCTLA-4-C, and WHcAg. Mice were immunized three times with indicated vaccines by i.m.
or s.c. routes and sacriﬁced on day 14 after the ﬁnal immunization. Splenocytes were separated and stimulated with p2 or p27 (2 μg/ml) for 7 days. (A) Serum IgG1 and IgG2a
anti-WHcAg antibody responses 14 days after each immunization. The error bar represents SEM from the mean value. (B) Frequencies of IFN-γþ CD8þ T cells to p2 or CD4þ
T cells to p27 induced by pWHcIm, pCTLA-4-C, and WHcAg. For each group 5–8 mice were included in three independent experiments. Data from each experiement were
pooled for A and B. (C) Degranulation and cytokine production in antigen-speciﬁc CD8þ T cells. (D) pWHcIm, pCTLA-4-C, and WHcAg induced different WHcAg-speciﬁc
CD8þ T cell cytotoxicity in peripheral blood on day 7–10 post the ﬁnal immunization. Six mice per group were analyzed, and data are one representative of two independent
experiments. Hair line represents the cut-off value of spontaneous killing.
Table 1
Summary and characteristics of pWHcIm-, pCTLA-4-C-, and WHcAg-induced
WHcAg-speciﬁc antibody and T cell immune responses.
Vaccine pWHcIm pCTLA-4-C WHcAg
Application route i.m. i.m. s.c.
IgG subtype
IgG1  þ þ
IgG2a þ þ þ
CD8þIFN-γþ þþ 7 
CD4þIFN-γþ þ þ 
In vivo killing þ  
Th bias Th1 dominant Th2 dominant Th2 type
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consideration). In this construct, the “a” determinant domain of
WHsAg was replaced in the WHV genome with the corresponding
region of HBsAg, resulting in a chimeric WHsAg that can be
detected with HBsAg ELISA. HI of mice with 10 μg plasmid via
the tail vein resulted in persistence of WHV for over 8 weeks,
based on HBsAg assays (Fig. 3). Over 75% of mice of the control
group were persistently positive for HBsAg and showed a very low
or undetectable WHcAg-speciﬁc CD8þ T cell response until the
end of experiment over 8 weeks. HBsAg and WHcAg were steadily
expressed in the liver during the whole experimental period (data
not shown).
Immunizations with pWHcIm and pCTLA4-C led to rapid
decrease of HBsAg levels in mice after HI, though they primed
two different types of WHcAg-speciﬁc immune responses (Fig. 3A
and B). The majority of immunized mice were negative for serum
HBsAg at day 3. Only one mouse in the pWHcIm group was
positive for HBsAg on day 63. This mouse had low anti-WHcAg
responses prior to HI (S/N of IgG1¼1, IgG2a¼2.3, no detectable
CD8þ T cells in PBMCs). Thus, both Th1- and Th2-dominant
immune responses to WHcAg led to efﬁcient viral reduction and
prevented the prolonged WHV persistence in mice, consistent
with the previous results with HBV. The recall responses in the
mice were monitored until week 5, and analyzed by detection of
WHcAg-speciﬁc, IFN-γ secreting CD8þ T cells in PBMCs after short
term ex vivo stimulation (Fig. 3C). The WHcAg-speciﬁc CD8þ T cell
responses were variable across the individual mice. However,
increased numbers of WHcAg-speciﬁc CD8þ IFN-γþ T cells were
mainly detected on days 7–14 and days 28–35 (Fig. 3D). WHcAg-
speciﬁc CD8þ IFN-γþ T cells appeared earlier in pWHcIm-
immunized mice than in pCTLA-4-C immunized mice and were
still detectable in the spleen or among inﬁltrating hepatic lym-
phocytes in some animals throughout the follow-up period,
although the response were already very low on day 63. A
summary of the data is given in Table 2. Thus, effective WHcAg-
speciﬁc CD8þ T cell responses could be induced independently on
the Th1/Th2 dominance of pre-primed immune responses, result-
ing ﬁnally in decrease of WHV replication.
Both pWHcIm and pCTLA-4-C vaccines reduced viral replication in
WHV tg mice
DNA vaccination may induce speciﬁc CD8þ T cells and sup-
press WHV replication in WHV tg mice (Kosinska et al., 2013;
Meng et al., 2014). We asked whether vaccination with pCTLA-4-C
could also reduce WHV replication in WHV tg mice. WHV tg mice
strain 1217 used in the experiments contains a wild-type WHV
Fig. 2. Challenge with Ad5WHc, viral clearance, and CD8 T cell recall responses. (A) The distribution of Ad5WHc vector in different organs in naive mice 48 h post
intravenously injection with 11010 pfu of Ad5WHc. (B) Experimental design of vaccination and challenge. Mice were immunized 3 times and then challenged with
11010 pfu of Ad5WHc on day 14 after the ﬁnal immunization. Splenocytes were isolated on days 4, 7, and 10 and stimulated with p13-21 (2 μg/ml) for 5 h. (C) Kinetics of
Ad5WHc clearance from the liver after challenge. (D) CD8þ T cells with respect to IFN-γ secretion and degranulation on days 4, 7, and 10 after Ad5WHc challenge.
(E) Functional analysis of CD8þ T cells with respect to IFN-γ, IL-2, and TNF-α production on days 4, 7, and 10 after Ad5WHc challenge. Six mice per group were analyzed, and
the error bar represents SEM from the mean value of duplicated experiments.
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genome and showed serum WHV DNA loads of 106–107 genome
equivalents/ml and were negative for anti-WHcAg antibody.
They received three immunizations with pCDNA3, pWHcIm, or
pCTLA-4-C.
DNA vaccinations induced similar anti-WHcAg antibody pro-
ﬁles in WHV tg mice like in C57BL/6 mice shown in Fig. 1A
(Fig. 4A). In contrast, the magnitude of the WHcAg-speciﬁc CD8þ
T cell response in WHV tg mice after pWHcIm immunization was
signiﬁcantly lower than that in wild type C57BL/6 mice shown in
Fig. 1B (Fig. 4B). Interestingly, WHV tg mice immunized with
pCTLA-4-C developed WHcAg-speciﬁc CD8þ T cells and, in part of
mice, WHcAg-speciﬁc CD4þ cells (Fig. 4B). These data indicated
that pCTLA-4-C-primed Th2-biased immune responses in WHV tg
mice are similar to those induced in wild type C57BL/6 mice.
WHcAg-speciﬁc T cells in WHV tg mice primed with pWHcIm
could also be detected by dimer staining and were able to produce
IFN-γ and degranulate as shown by CD107a assay (Fig. 4C). In
contrast, only few to no IFN-γþ or CD107aþ T cells could be
detected in WHV tg mice that received pCTLA-4-C, indicating that
this DNA vaccine does not prime multifunctional CD8þ T cells
in mice.
Finally, serum WHV DNA loads in WHV tg mice were deter-
mined before and after DNA vaccination. Application of plasmid
DNA alone led to a slight decrease of serum WHV DNA (pcDNA3
group), likely due to unspeciﬁc triggering of host innate responses.
WHV DNA was strongly reduced (4 log3) and became undetect-
able in 3 of 10 WHV tg mice after pWHcIm vaccination (Fig. 4D).
Mice in the pCTLA-4-C group showed a weaker but signiﬁcant
decrease in WHV DNA loads (E log2, Fig. 4D). The WHV DNA and
RNA levels in WHV tg mice were relatively low but were also
slightly reduced after vaccination. These results indicated that
both pWHcIm and pCTLA-4-C DNA vaccines were able to elicit
WHcAg-speciﬁc antibody and T cell responses that reduced WHV
replication in WHV tg mice.
Discussion
In the present study, we tested three different vaccines to
WHcAg and their combinations in the mouse models. Protein or
DNA vaccines base on WHcAg were used according to their most
compatible doses and routes of immunization according to the
Fig. 3. Both pre-existing Th1- and Th2-dominant responses accelerated viral clearance in mice after HI challenge. Mice were immunized three times and then challenged
with pBS/WHV-Sa1.3 replication-competent plasmid by HI on day 14 after the ﬁnal immunization. Serum samples were taken from mice on the indicated time points to
monitor serum HBsAg or CD8þ T cell response. PBMCs and intrahepatic lymphocytes were isolated on day 35. Splenocytes were analyzed following in vitro stimulation with
p2 (2 μg/ml) for 7 days, while intrahepatic lymphocytes were stimulated with p13-21 (2 μg/ml) for 5 h. (A) and (B) Kinetics of HBsAg clearance following challenge of
different plasmid pre-treated animals. (C) Kinetics of CD8þ T cell responses in PBMCs post challenge by HI. (D) CD8þ T cell responses in the spleen and liver on day 35 post
challenge by HI. The error bar represents SEM from the mean percentage of CD8þ IFN-γþ T cells. For each group 5–8 mice were included. Data are one representative of two
independent experiments.
Table 2
Summary of immunological and virological parameters in mice after immunization and WHV HI challenge.
Vaccine group PBS pWHcIm pCTLA-4-C
Pre-challenge
anti-WHc IgG IgG1  , IgG2a  IgG1  , IgG2a þ IgG1þ IgG2a þ
WHcAg-speciﬁc CD8 T cell response  þ 7
Post-challenge
WHcAg-speciﬁc CD8 T cell response
(PBMCs)
Gradual increase and peak at
day 35
Peak at days 7–14 and 28–
35
Peak at days 7–14 and
28–35
Follow-up days 35–63 post-
challenge
Splenic WHcAg-speciﬁc CD8 T cell response 1/7* 2/5 3/5
intrahepatic WHcAg-speciﬁc CD8 T cell
response
0/7 4/5 1/5
anti-HBs 0/7 0/5 0/5
anti-WHc 0/7 5/5 5/5
HBsAg in the liver 5/7 1/5 0/5
WHcAg in the liver 5/7 0/5 0/5
n Indicates number of positive animals in total animals.
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Fig. 4. pWHcIm and pCTLA-4-C induced antigen-speciﬁc immune responses in WHV transgenic mice. WHV transgenic mice (strain 1217) were immunized three times and
sacriﬁced 14 days after the ﬁnal immunization. Splenocytes were isolated and stimulated with p2 or p27 (2 μg/ml) for 7days. Cells were restimulated with corresponding
peptides and analysed following staining with antibodies to CD8, IFN-γ, CD107a, or p13-21 loaded H-2Db dimers. (A) Anti-WHc IgG subtypes in serum. (B) Frequency of IFN-
γ-secreting CD8þ T cells to p2 and CD4þ T cells to p27. (C) Functional analysis of WHcAg-speciﬁc CD8þ T cells with respect to IFN-γ secretion and degranulation.
(D) Comparison of serum WHV DNA viral loads, hepatic WHV DNA, and RNA levels before and after three immunizations with pWHcIm or pCTLA-4-C. Pre-im, pre-
immuization; dashed line, detection limit. The error bar represents SEM from the mean value. For each group 6–8 mice were included. Data were pooled from two
independent experiments with similar results.
E. Zhang et al. / Virology 475 (2015) 56–65 61
previous experiments. The vaccines used in this study induced
WHcAg-speciﬁc immune responses with signiﬁcant differences in
the strength of CD8þ T-cell responses and antibody subtype
ratios. Clearly, pWHcIm primed a typical Th1 dominant immune
response, while pCTLA4-C and WHcAg protein induced immune
responses with Th2 bias. The different features of the immune
responses induced by protein and DNA vaccines may be partly a
result of the route of immunization and the way of antigen
presentation, as plasmid and protein vaccines are differently
presented by DC and thereby promote different types of T helper
cells. As shown in the previous studies, all three vaccines con-
ferred protection against WHV challenge in woodchucks (Lu et al.,
2005; Menne et al., 1997; Schodel et al., 1993b). Our results
showed that WHcAg protein based vaccine did not induce any
detectable CD8þ T cell response, thus, the recall response after
WHV challenge may be critical to control viral infection in
immunized woodchucks.
Our immunizations were carried out in mice without pre-
existing anti-WHc antibodies. In chronically HBV-infected patients
or WHV-infected animals, anti-HBc and anti-WHc antibodies are
present, respectively. In such cases, therapeutic vaccines may
boost the pre-existing antibody responses, similarly to the situa-
tion to boost vaccination in individuals who received initial doses
of vaccines and developed antibody responses. In our experiments,
mice also developed anti-WHc after initial vaccination, so all boost
vaccinations were carried out under the conditions with pre-
existing anti-WHc antibodies. Our results presented in Supple-
ment Fig. 3 showed clearly that the pre-existing anti-WHc anti-
body responses may inﬂuence the late vaccinations while the late
vaccinations could also change the nature of anti-WHc antibody
responses.
We carefully analysed recall responses in our mouse models.
Challenge with a replication-incompetent adenoviral vector expres-
sing WHcAg allowed for a more detailed characterization of
antigen-speciﬁc T cell responses after re-exposure to WHcAg. In
all mice vaccinated against WHcAg, WHcAg-speciﬁc CD8þ T cells
were expanded after challenge. This expansion occurred rapidly in
mice with pre-existing Th1-dominant responses but with delayed
kinetics in mice with Th2-dominant and Th2 type responses.
Moreover, WHcAg-speciﬁc CD8þ T cells from the three groups
displayed different phenotypes. The majority of WHcAg-speciﬁc
CD8þ T cells produced IFN-γ but did not show degranulation. Thus,
the pre-existing Th2-biased immune responses do not prevent
induction of the CD8þT cell response but inﬂuence its kinetics
and functionality. Despite these differences in the recall responses,
both Th1- and Th2-dominant responses were protective against
WHV challenge by HI. These results provide an explanation for how
a vaccine that induces Th2-biased responses could protect against
hepadnaviral infection, as has been observed in chimpanzees and
woodchucks (Menne et al., 1997; Murray et al., 2005).
Previously, we assessed the protective values of the immune
responses primed by two different DNA vaccines pHBc and pCTLA-
4-HBc that are the equivalents to pWHcIm and pCTLA4-C. Mice
immunized with pHBc and pCTLA-4-HBc developed Th1- and -2
biased immune responses to HBcAg, respectively. Challenge by HI
of pAAV/HBV1.2 showed that HBsAg clearance was completed
within 16 days in immunized mice, while HBsAg still remained
to be detectable in more than 50% of the control mice on day 22.
Stronger HBcAg-speciﬁc T-cell responses were primed by pHBc
correlating with a more rapid decline of intrahepatic HBcAg
expression, while anti-HBsAg antibody response developed
rapidly in the mice immunized with pCTLA-4-HBc. Therefore, the
Th1/Th2 bias of vaccine-primed immune responses did not sig-
niﬁcantly change the kinetic but inﬂuences the mode of viral
clearance. Consistent with the published study, we showed that
both pWHcIm and pCTLA-4-C immunizations led to a decrease of
WHV replication after HI challenge in mice. Here, we further
studied the relationship between the pre-primed immune
responses and the mode of viral clearance. We reﬁned the analysis
of the recall responses to determine the speciﬁc CD8þ T cell
responses to WHcAg after the challenge. WHcAg-speciﬁc
CD8þ IFN-γþ T cells were present in peripheral blood of
pWHcIm-immunized mice but decreased shortly after HI, likely
due to the recruitment to the liver. Such T cells reappeared usually
at day 7 or 14 and remained detectable through the experimental
period. Interestingly, the pCTLA-4-C immunized mice also devel-
oped signiﬁcant WHcAg-speciﬁc CD8þ IFN-γþ T cells showed at
later time points. WHcAg-speciﬁc CD8þ IFN-γþ T cells were
detectable in the liver of some mice of both immunized groups.
Again, the Th2 bias of pCTLA-4-C primed immune responses in
mice did not delay viral control after HI but change the kinetics of
WHcAg-speciﬁc CD8þ IFN-γþ T cell responses.
Surprisingly, immunization of WHV tg mice with pCTLA-4-C
induced signiﬁcant WHcAg-speciﬁc CD8þ T cell responses.
Clearly, these CD8þ T cells were functionally limited compared
to those induced by pWHcIm. They may only be able to produce
IFN-γ or to degranulate but are not multifunctional. Nevertheless,
a signiﬁcant reduction in WHV DNA loads occurred after immu-
nizations of mice with pCTLA-4-C. In future experiments, it would
be interesting to examine the properties of the antigen-speciﬁc T
cells and their antiviral functions in detail. Such studies may help
us to understand why the functions of antigen-speciﬁc CD8þ T
cells in chronic HBV and WHV infections are limited. In some mice,
pCTLA-4-C induced CD4þ T cells, which may contribute to the
therapeutic effect.
In this study, we tested different prime-boost immunizations
combining DNA and protein vaccines. The results were rather
discouraging as such combinations did not show obvious advan-
tage. In this experiment, Th1-biased vaccines could boost antigen-
speciﬁc CD8þ T cell immune responses in the presence of pre-
primed Th2-biased immune responses, but with signiﬁcantly
reduced effectiveness. In a recent study, we used DNA
vaccination-adenoviral vector boost and observed great improve-
ment of speciﬁc CD8þ T-cell responses (Kosinska et al., 2012).
Certainly, the usefulness of combined DNA and protein vaccines
needs to be tested from case to case. The ﬁndings in the present
study do not have an immediate impact on clinical practice but
add some data to our understanding about the viral control by
vaccination.
In conclusion, we primed deﬁned antigen-speciﬁc immune
responses with Th1 and Th2 biases. We demonstrated that pre-
existing immune responses strongly inﬂuenced the functionality
and kinetics of the antigen-speciﬁc T cells in recall responses.
Clearly, vaccines that prime Th1-dominant immune responses
induced more efﬁciently multifunctional CD8þ T cells in
immune-tolerant hosts and are therefore suitable as therapeutic
vaccines. However, vaccines that prime Th2-biased immune
responses to HBV proteins could be equally effective as prophy-
lactic vaccines. As such vaccines are able to induce stronger CD4þ
T cell responses and provide so call “intermolecular help” to
support broad immune responses against other viral components,
its value in the therapeutic setting needs more attention in the
future. Nevertheless, both types of vaccines are able to induce
speciﬁc immune responses and contribute to the antiviral actions.
Materials and methods
Plasmids, protein, and peptides
The pWHcIm and pCTLA-4-C plasmids used for DNA vaccina-
tion were described previously (Lu et al., 2005). Plasmid pWHcIm
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contains the WHV C region of WHV8 in pcDNA3.1 vector, while
pCTLA-4-C contains the coding regions for the extracellular
domain of woodchuck CTLA-4 fused with WHV C coding sequence.
WHcAg protein was expressed in E. coli and puriﬁed by chroma-
tography with Sepharose 6 and sucrose gradient centrifugation
(Zhang et al., 2006). WHcAg-derived peptides were purchased
from EMC microcollections (Tubingen, Germany) and were
described previously (Kosinska et al., 2012). For stimulation of
murine lymphocytes, the following two 15-mer and single 9-mer
peptides were used: p2 (aa 6–20, YKEFGSSYQLLNFLP), containing a
CD8þ T cell epitope; p27 (aa131–145, PYRPPNAPILSTLPE), contain-
ing a CD4þ T cell epitope; and p13-21 (YQLLNFLPS), the precise
Db-restricted CD8þ T cell epitope present within p2. An unrelated
cytomegalovirus (CMV)-derived peptide (YILEETSVM) served as a
negative control.
Animal experiments
C57BL/6 mice were purchased from Harlan Laboratories Inc.,
Germany, or the Animal Center of Beijing province, China. WHV
transgenic mice (strain 1217) were generated and bred in the
Central Animal Laboratory of University Hospital Essen (Meng
et al., 2014). The Tg mice strain 1217 harbors a wild-type WHV
genome and show sex- and age-dependent viral replication in the
liver. The 1217 tg mice were also partially immune tolerant to
WHV antigens. Experiments were conducted in accordance with
the Guide for the Care and Use of Laboratory Animals and were
reviewed and approved by the local Animal Care and Use Com-
mittee (Central Animal Laboratory, University of Duisburg-Essen,
Essen, Germany, and the district government of Düsseldorf,
Germany; or Tongji Medical College, Wuhan, China). All mice were
females and at 8–10 weeks of age at the time the experiments
were initiated.
Immunization of mice
For plasmid DNA immunization, mice were pretreated with
50 μl cardiotoxin (10 μM) via intramuscular injection into M.
tibialis anterior. After 1 week, 50 μg of plasmids in phosphate-
buffered saline (PBS) at a concentration of 1 mg/ml was injected
into the same muscle of both legs. The control mice received
100 μl PBS. For WHV transgenic mice, the controls received 100 μl
of the empty vector pCDNA3 using the technique described above.
For WHcAg protein immunizations, 10 μg protein was diluted into
50 μl PBS and emulsiﬁed in an equal volume of Freund’s incom-
plete adjuvant. The protein emulsion was administered by sub-
cutaneous injection at 4–5 points on the back. The immunization
was repeated twice at 2-week intervals. The mice were sacriﬁced
2 weeks after the ﬁnal immunization. A minimum of 8 mice were
included in each group.
Serology and detection of WHV DNA
Antibodies to WHcAg (anti-WHcAg) of the IgG, IgG1, and IgG2a
subtypes were detected in mouse serum samplesby speciﬁc
enzyme linked immunosorbent assays (ELISAs) as described pre-
viously (Lu et al., 2005). Serum HBsAg and antibodies to HBsAg
(anti-HBsAg) were detected by ELISA using commercial diagnostic
kits (Kehua, Shanghai, China). The cut-off value was set as 2.1-fold
the mean value of the negative controls. For detection of serum
WHV DNA, total DNA was then extracted using the QIAamp DNA
Mini Kit according to the manufacturer’s instructions (Qiagen,
Germany). Each serum sample was pretreated with 30 units of
DNase I (TAKARA, Japan) at 37 1C overnight to eliminate residual
plasmid DNA used for HI before total DNA was extracted. WHV
DNA was detected by real-time PCR as described previously (Lu
et al., 2005; Yin et al., 2011). The primers used for PCR are listed in
Table 3 (Frank et al., 2007; Kosinska et al., 2012; Lu et al., 2005).
Detection of WHV DNA and RNA in liver tissue
Mice were sacriﬁced and liver tissue was frozen in liquid
nitrogen. Total liver DNA was isolated using the QIAamp DNA
Mini Kit according to the manufacturer’s instructions (Qiagen,
Germany). Total RNA was extracted from liver tissue samples with
TRIzol reagent (Invitrogen) according to the manufacturer’s
instructions. WHV RNA and DNA were detected by real time-PCR
and real time RT-PCR as described previously (Frank et al., 2007).
Preparation and stimulation of mouse PBMCs and splenocytes
Splenocyte suspensions were prepared by homogenization and
cultured as described previously (Dietze et al., 2011). Up to
1-2106 splenocytes per well were plated in 96-well plates. For
isolation of mouse PBMCs, each 100 μl sample of anticoagulant-
treated blood was mixed with 1 ml Buffer EL (Qiagen, Germany)
for 5 min to lyse red blood cells, washed twice with 50 ml PBS,
resuspended in 100 μl complete RPMI1640 medium, and then
seeded in a single well of a 96-well plate. Individual peptides were
added to the wells at a ﬁnal concentration of 2 μg/ml. For in vitro
stimulation, splenocytes were incubated with peptides p2 or p27
and recombinant mouse IL-2 (10 U/ml) added 3 days after plating
and then restimulated after 6–7 days. For ex vivo analysis, PBMCs
or splenocytes were stimulated with p13-21 (2 μg/ml) in the
presence of Brefeldin A (BFA, 4 μg/ml) for 5 h.
Flow cytometry with cell surface and intracellular cytokine staining
Cell surface staining was performed using BD Biosciences or
eBioscience reagents (Dietze et al., 2011; Zelinskyy et al., 2011).
The T cell antibodies used were anti-CD4 (H129.19), anti-CD8 (53-
6.7), anti-CD43 (eBioR2/60), and anti-CD107a (1D4B). Dead cells
were excluded from the analysis by 7-AAD staining (BD Bios-
ciences). Next, cells were washed, permeabilized using the Cytoﬁx/
Cytoperm intracellular staining kit (BD Biosciences), and stained
with cytokine-speciﬁc mAbs including IFN-γ (XMG1.2), IL-2 (JES6-
5H4), and TNF-α (MP6-XT22).
Mouse DimerX (Recombinant Soluble Dimeric H-2Db:Ig Fusion
Protein)was purchased from BD Biosciences. DimerX was pre-
loaded with p13-21 at 37 1C overnight and incubated with sple-
nocytes or PBMCs at 4 1C for 1 h to facilitate its binding to the p13-
21-speciﬁc CD8þ T cells. Afterwards, cells were stained with an
anti-mouse IgG-PE (BD Biosciences) that speciﬁcally recognises
DimerX.
Flow cytometry data were acquired on FACS Caliburor or FACS
LSR II ﬂow cytometers (BD Biosciences), with 100,000–150,000
lymphocyte-gated events collected per sample. Analyses were
performed using FlowJo (Tree Star) software.
In vivo cytotoxicity assay
A modiﬁed version of the in vivo CTL assay described by Barber
et al. was used to measure cytotoxicity in vaccinated mice (Barber
andWherry and Ahmed, 2003; Dietze et al., 2011). Splenocytes
from naïve mice were loaded with 4 μM p13-21 and stained with
36 nM 5-(and 6-)carboxyﬂuorescein diacetate succinimidyl ester
(CFSE, Invitrogen). As a control, unloaded splenocytes were stained
with 9 nM CFSE. Each of 1107 loaded or unloaded splenocytes
were mixed and transferred intravenously into naïve or vaccinated
mice. Eight hours after the transfer, spleens and blood were
harvested from recipient mice and cell suspensions prepared from
the tissues. Target cells were distinguished from recipient cells
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based on CFSE staining. The percentage of killing was calculated
using the following equation: 100([(% peptide-loaded cells in
vaccinated mice/% unloaded cells in vaccinated mice)/(% peptide-
loaded cells in naïve mice/% unloaded cells in naïve mice)]100).
Challenge with a recombinant adenoviral vector expressing WHcAg
A recombinant adenoviral vector expressing WHcAg (Ad5WHc)
was generated previously (Kosinska et al., 2012). To infect mice,
11010 pfu of Ad5WHc were injected intravenously. For detection
of adenoviral DNA, total DNA was extracted from 200 μl of mouse
serum samples or 10 μg of liver tissues with the QIAamp DNA
Blood Mini Kit (Qiagen, Germany) according to the manufacturer’s
protocol. Adenoviral DNA was detected by TaqMAN real-time PCR
using the primers listed in Table 3 (Berciaud et al., 2012; Heim
et al., 2003) with the LightCyclers FastStart DNA Master HybProbe
kit (Roche, USA).
WHV challenge by hydrodynamic injection (HI) of pBS/WHV-Sa1.3
plasmid
The plasmid pBS/WHV-Sa1.3 containing a 1.3-fold overlength
WHV genome was constructed in our laboratory (Pan et al., under
consideration). The “a”-determinant of WHsAg was replaced with
the corresponding fragment from HBsAg, resulting in a chimeric
WHsAg that is reactive in an HBsAg-speciﬁc ELISA. On day 14 after
the ﬁnal immunization, 10 μg of pBS/WHV-Sa1.3 diluted in a 0.9%
NaCl solution was injected into the tail veins of mice in a volume
equivalent to 8% of each mouse’s body weight (Berciaud et al.,
2012). The total volume was injected within 8 s. Serum specimens
were collected and assayed for HBsAg, anti-HBs and anti-WHcAg
antibodies, and WHV DNA at the indicated times. Mice were
sacriﬁced 8 weeks after HI. The splenocytes and liver-inﬁltrating
lymphocytes were isolated for intracellular cytokine staining (Yang
et al., 2010).
Statistical analysis
Statistical analyses were performed using GraphPad Prism
version 5 (GraphPad Software Inc., San Diego, CA). Statistical
differences were analyzed with ANOVA One Way analysis of
variance followed by Bonferroni’s Multiple Comparison Test. The
P-values o0.05 were considered signiﬁcant.
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